■ Published papers
|
Original article
|
|
1.
|
ISHIHARA Hiroki†, NISHIMURA Koichi, NEMOTO Yuki, MIZOGUCHI Shinsuke, NAKAYAMA Takayuki, FUKUDA Hironori, SHIMMURA Hiroaki, HASHIMOTO Yasunobu, YOSHIDA Kazuhiko, IIZUKA Junpei, KONDO Tsunenori, TAKAGI Toshio：
Effect of age on treatment outcomes of first-line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma.
Geriatrics & Gerontology International
25
(8)
：1082-1088
, 2025.8
DOI:10.1111/ggi.70105
|
|
2.
|
ISHIHARA Hiroki†*, NEMOTO Yuki, MIZOGUCHI Shinsuke, NISHIMURA Koichi, FUKUDA Hironori, YOSHIDA Kazuhiko, SHIMMURA Hiroaki, HASHIMOTO Yasunobu, IIZUKA Junpei, KONDO Tsunenori, TAKAGI Toshio：
Comparative analysis of outcomes for patients with advanced renal cell carcinoma: Immuno-oncology era versus tyrosine kinase inhibitor era in the IMDC favorable-risk group.
Anticancer research
45
(4)
：1643-1652
, 2025.4
DOI:10.21873/anticanres.17545
|
|
Other
|
|
1.
|
TAKAGI Toshio†, YOSHIDA Kazuhiko, FUKUDA Hironori, ISHIHARA Hiroki, NAKAMURA Kazutaka, NEMOTO Yuki, MIZOGUCHI Shinsuke, IIZUKA Junpei, KONDO Tsunenori：
Impact of cytoreductive nephrectomy on immune checkpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies for metastatic renal cell carcinoma with primary kidney tumors.
The Journal of urology
213
(S5)
：e1007-e1007
, 2025.5
|
|
2.
|
NAKAMURA Kazutaka†, KONDO Hanae, NEMOTO Yuki, ISHIHARA Hiroki, FUKUDA Hironori, SHIMMURA Hiroaki, YOSHIDA Kazuhiko, KONDO Tsunenori, TAKAGI Toshio：
Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma.
The Journal of urology
213
(S5)
：e1009-e1010
, 2025.5
|
|
3.
|
NAKAMURA Kazutaka†, KONDO Hanae, INAKAWA Toru, NEMOTO Yuki, KOBARI Yuki, YOSHIDA Kazuhiko, IIZUKA Junpei, KONDO Tsunenori, TAKAGI Toshio：
Treatment outcomes of enfortumab vedotin in ineligible patients from the EV-301 trial.
The Journal of urology
213
(S5)
：e1261-e1261
, 2025.5
|
|
4.
|
YOSHIDA Kazuhiko†, KONDO Tsunenori, KOBARI Yuki, ISHIHARA Hiroki, FUKUDA Hironori, IIZUKA Junpei, TAKAGI Toshio：
Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study.
The Journal of urology
213
(S5)
：e17-e18
, 2025.5
|
|
5.
|
ISHIHARA Hiroki†, NISHIMURA Koichi, NAKAYAMA Takayuki, FUKUDA Hironori, YOSHIDA Kazuhiko, IIZUKA Junpei, KONDO Tsunenori, TAKAGI Toshio：
Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma.
The Journal of urology
213
(S5)
：e490-e491
, 2025.5
|
|
To the top
|
|
■ Academic conference presentation
|
1.
|
◎NAKAMURA Kazutaka, KONDO Hanae, INAKAWA Toru, NEMOTO Yuki, KOBARI uuki, YOSHIDA Kazuhiko, IIZUKA Junpei, KONDO Tsunenori, TAKAGI Toshio：
Treatment outcomes of enfortumab vedotin in ineligible patients from the EV-301 trial.
2025 American Urological Association Annual Meeting,
Las Vegas, USA,
2025/04
|
|
2.
|
◎HIRAI Toshihito, OKI Rikako, KIJIMA Yu, KATSURAYAMA Nanaka, FUKUDA Hironori, SHIMIZU Tomokazu, TOKITA Daisuke, ISHIDA Hideki, TAKAGI Toshio：
Gene profile of old donor kidney related to kidney function before and after kidney transplantation.
2025 American Urological Association Annual Meeting,
Las Vegas, USA,
2025/04
|
|
3.
|
◎NAKAMURA Kazutaka, KONDO Hanae, NEMOTO Yuki, ISHIHARA Hiroki, FUKUDA Hironori, SHIMMURA Hiroaki, YOSHIDA Kazuhiko, KONDO Tsunenori, TAKAGI Toshio：
Comparison of clinical outcomes between cabozantinib+nivolumab and lenvatinib+pembrolizumab in advanced renal cell carcinoma.
2025 American Urological Association Annual Meeting,
Las Vegas, USA,
2025/04
|
|
4.
|
◎TAKAGI Toshio, YOSHIDA Kazuhiko, FUKUDA Hironori, ISHIHARA Hiroki, NAKAMURA Kazutaka, NEMOTO Yuki, MIZOGUCHI Shinsuke, IIZUKA Junpei, KONDO Tsunenori：
Impact of cytoreductive nephrectomy on immunecheckpoint inhibitor therapy: Treatment outcomes of immune inhibitors combination therapies formetastatic renal cell carcinoma with primary kidneytumors.
2025 American Urological Association Annual Meeting,
Las Vegas, USA,
2025/04
|
|
5.
|
◎ISHIHARA Hiroki, NISHIMURA Koichi, NAKAYAMA Takayuki, FUKUDA Hironori, YOSHIDA Kazuhiko, IIZUKA Junpei, KONDO Tsunenori, TAKAGI Toshio：
Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma.
2025 American Urological Association Annual Meetin,
Las Vegas, USA,
2025/04
|
|
6.
|
◎YOSHIDA Kazuhiko, KONDO Tsunenori, KOBARI Yuki, ISHIHARA Hiroki, FUKUDA Hironori, IIZUKA Junpei, TAKAGI Toshio：
Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy for renal cell carcinoma: A propensity score matching study.
2025 American Urological Association Annual Meeting,
Las Vegas, USA,
2025/04
|
|
7.
|
近藤恒徳：
増加する高齢者腎細胞癌への治療アプローチ～実臨床データをどう解釈するか？～.
第38回日本老年泌尿器科学会 ランチョンセミナー2,
東京,
2025/07
|
|
8.
|
◎雲野陽大, 福田洋典, 石原弘喜, 吉田一彦, 飯塚淳平, 近藤恒徳, 長嶋洋治, 高木敏男：
当院で診断されたTFE3再構成腎細胞癌の臨床病理学的特徴.
第55回腎癌研究会,
東京,
2025/07
|
|
9.
|
◎石原弘喜, 福田洋典, 山下理宇, 平井敏仁, 西村紘一, 根本侑樹, 溝口晋輔, 吉田一彦, 飯塚淳平, 近藤恒徳, 長嶋洋治, 高木敏男：
網羅的遺伝子発現解析および腫瘍浸潤免疫細胞プロファイリングによる非淡明細胞型腎細胞がんに対する免疫チェックポイント阻害薬治療効果に与える影響の解明.
第55回腎癌研究会,
東京,
2025/07
|
|
10.
|
◎中村和貴, 根本侑樹, 小針悠希, 石原弘喜, 福田洋典, 吉田一彦, 新村浩明, 小林裕, 橋本恭伸, 近藤恒徳, 高木敏男：
進行腎癌におけるカボザンチニブ+ニボルマブとレンバチニブ+ペムブロリズマブの有効性および安全性の比較.
第55回腎癌研究会,
東京,
2025/07
|
|
11.
|
◎葛山七花：
当院における進行性腎細胞癌に対するペムブロリヅマブによる術後補助薬物療法の予後及び安全性の検討.
第55回腎癌研究会記念大会,
東京,
2025/07
|
|
12.
|
◎西村紘一：
進行腎細胞癌に対する一次治療免疫複合療法後の二次治療分子標的薬の検討.
第55回腎癌研究会記念大会,
東京,
2025/07
|
|
13.
|
◎HORIUCHI Toshihide, KATSURAYAMA Nanaka, NAKAMURA Kazutaka, NISHIMURA Koichi, TOKI Daisuke, KOBAYASHI Hirohito, KONDO Tsunenori, TAKAGI Toshio：
Initial outcomes of prostatic urethral lift for benign prostatic hyperplasia in our hospital.
第112回日本泌尿器科学会総会,
福岡,
2025/04
|
|
14.
|
◎NISHIMURA Koichi, KATSURAYAMA Nanaka, NAKAMURA Kazutaka, HORIUCHI Toshihide, KOBAYASHI Hirohito, TOKI Daisuke, KONDO Tsunenori, TAKAGI Toshio：
Evaluation of robotic-assisted versus open radical cystectomy in the elderly.
第112回日本泌尿器科学会総会,
福岡,
2025/04
|
|
15.
|
◎Nakajima Nao, Hirai Toshihito, Moriyama Ikumi, Saito Ayaka, Okada Daigo, Unagami Kohei, Shimizu Tomokazu, Ishida Hideki, Takagi Toshio：
Assessment of reoperation after kidney transplantation.
第112回日本泌尿器科学会総会,
福岡,
2025/04
|
|
16.
|
◎AKASAKI Momoko, SAWADA Yugo, UEMATSU Hirotaka, TANAKA Masumi, OKADA Daigo, MORIYAMA Ikumi, TAKAGI Toshio：
A case of recurrent rectal prolapse with cystocele treated by robot-assisted rectopexy and robot-assisted sacrocolpopexy.
第112回日本泌尿器科学会総会,
福岡,
2025/04
|
|
17.
|
◎FUKUDA Hironori, ISHIHARA Hiroki, HIRAI Toshihito, TOKITA Daisuke, YAMASHITA Riu, KITANO Shigehisa, AOKI Kazunori, YOSHIDA Kazuhiko, IIZUKA Junpei, KONDO Tsunenori, TAKAGI Toshio：
Impact of histological subtypes on the efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma.
第112回日本泌尿器科学会総会,
福岡,
2025/04
|
|
18.
|
◎KATSURAYAMA Nanaka, ISHIHARA Hiroki, NEMOTO Yuki, MIZOGUCHI Shinsuke, FUKUDA Hironori, YOSHIDA Kazuhiko, IIZUKA Junpei, SHIMMURA Hiroaki, HASHIMOTO Yasunobu, KONDO Tsunenori, TAKAGI Toshio：
Prognostic impact of polypharmacy in immune checkpoint inhibitor combination therapy for advanced renal cell carcinoma.
第112回日本泌尿器科学会総会,
福岡,
2025/04
|
|
19.
|
◎KOBARI Yuki, IIZUKA Junpei, KONDO Hanae, ICHIOKA Makiko, WATANABE Shun, HORIUCHI Toshihide, MIZOGUCHI Shinsuke, YOSHIDA Kazuhiko, SHIMMURA Hiroaki, HASHIMOTO Yasunobu, KONDO Tsunenori, KOBAYASHI Hiroshi, TAKAGI Toshio：
Safety and efficacy of enfortumab vedotin for metastatic urothelial carcinoma in over 80 years old patients: Multi-center retrospective study in Japan.
第112回日本泌尿器科学会総会,
福岡,
2025/04
|
|
20.
|
◎NAKAI Keisuke, NISHIMURA Koichi, KATSURAYAMA Nanaka, ENDO Takanori, NAKAMURA Kazutaka, HORIUCHI Toshihide, TOKI Daisuke, KOBAYASHI Hirohito, KONDO Tsunenori, TAKAGI Toshio：
Perioperative outcome of surgery for renal cell carcinoma with inferior vena cava thrombus following medical therapy in the era of immune checkpoint inhibitors.
第112回日本泌尿器科学会総会,
福岡,
2025/04
|
|
21.
|
近藤恒徳：
IVC塞栓症例に対する治療：プレサージカル薬物療法の立場から―初診時有転移症例（M1例）―.
第112回日本泌尿器科学会総会,
福岡,
2025/04
|
|
22.
|
◎ISHIHARA Hiroki, OMAE Kenji, NEMOTO Yuki, MIZOGUCHI Shinsuke, KATSURAYAMA Nanaka, FUKUDA Hironori, YOSHIDA Kazuhiko, SHIMMURA Hiroaki, HASHIMOTO Yasunobu, IIZUKA Junpei, KONDO Tsunenori, TAKAGI Toshio：
Outcome comparison between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib for advanced renal cell carcinoma.
第112回日本泌尿器科学会総会,
福岡,
2025/04
|
|
23.
|
◎NEMOTO Yuki, ISHIHARA Hiroki, FUKUDA Hironori, YOSHIDA Kazuhiko, IIZUKA Junpei, SHIMMURA Hiroaki, KONDO Tsunenori, TAKAGI Toshio：
Details of adrenal insufficiency as an immune-related adverse events in combination immune checkpoint therapy for advanced renal cell carcinoma.
第112回日本泌尿器科学会総会,
福岡,
2025/04
|
|
24.
|
◎菊池華代：
転移性尿路上皮癌に対してEVP療法施行後、間質性肺炎を来した2症例.
第34回 Young Urologists Congress （YUC）,
東京,
2025/07
|
|
25.
|
◎西村紘一：
膀胱癌治療の最前線～最新のレジメンと臨床成績～.
第16回東京都区東北部薬剤 地域連携包括協議会研究会,
東京,
2025/05
|
|
26.
|
◎堀内俊秀：
前立腺吊り上げ術後の経過.
キッセイ薬品社員研修会,
東京,
2025/05
|
|
Display 5 items
|
|
Display all(26)
|
|
To the top
|
|
